Ranbaxy Talks Up De-risking Strategy To Offset Impact Of Toansa Site Ban
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy fielded a volley of questions during a fourth quarter earnings call on the impact of the latest ban imposed by FDA on its Toansa, India site. Contrary to general estimates, Ranbaxy clarified the impact of the ban will be very limited on its North American business.